from dry Guthrie blood spots from a local sample of 1,005 female newborns (population controls), for the size of the FMR1 CGG repeat using a PCR technique. Results We found a significant excess (8.2%) of GZ carriers compared with 5.2% in the control sample, with a P value of 0.009 for the difference in proportions. Conclusion FMR1 gray zone alleles are a significant risk factor for parkinsonism in females. These population data and occasional reports of FXTAS-like or parkinsonian manifestations in carriers suggest possible mechanisms whereby the effects of these alleles synergize with the existing pathologies underpinning parkinsonism. The multiple causes of Parkinson's disease (PD) result in a spectrum of phenotypes within the broad clinical picture of bradykinesia, rigidity and/or resting tremor, and postural instability, with or without Lewy body formation. A number of rare genetic causes have been established (notably LRRK2 and a-synuclein mutations), although not all (e.g., Parkin mutations) faithfully recapitulate the a-synuclein deposits in cytoplasmic Lewy bodies, which are the pathological hallmark of idiopathic Parkinson's disease (iPD). 1 It was recently discovered that heterozygotes for mutations in the glucocerebrosidase gene have a 20-to 30-fold increased risk of developing PD, with an earlier age of onset and greater cognitive impairment than in the idiopathic disease. 2 In 2009, we reported that intermediate-range (GZ) alleles of the fragile X mental retardation 1 (FMR1) gene, containing small (41-54) CGG repeat expansions, were significantly over-represented in a cohort of 228 male iPD patients from two Australian states. 3 Comparison with the frequency of GZ alleles in a sample of 578 Guthrie spots from consecutive local male newborns showed an increase in GZ carriers in the iPD patient cohorts (6.8% vs. 3.3% in controls), with an odds ratio (OR) of 2.36 (95% confidence interval [CI]: 1.20-4.63). A more recent screening of a larger independent cohort of 817 males from the Queensland Parkinson's Project (QPP) also showed a 2.5-fold excess of GZ carriers 4 compared to the same sample of newborn controls. In both studies, the patients had been diagnosed using the UK Brain Bank criteria. 5 We discussed the inconsistent results from some other, earlier studies of males with iPD, which were attributed to inadequate sample sizes, falling well below the frequency stabilization threshold, 4 and to other major problems inherent in this type of screening, such as the choice of control population or ascertainment issues.
Moreover, comparison of the prevalence rates with those early surveys is not straightforward because the definitions of the GZ alleles, especially of the lower threshold, varied between 35 and 45 CGG repeats. 6 Our own population studies, however, as well as more recent surveys, have considered that the lower repeat number should be 40 to 41. This is based on the threshold for elevation of FMR1 mRNA blood levels 7 that were originally linked to neurotoxicity in carriers of FMR1 premutations in the 55-to 200-CGG range. [8] [9] [10] [11] The lower end of this particular range was determined by the potential for expansion into the full mutation (>200) over a single generation. 12 Evidence from female cohorts is still limited. An excess (12%) of GZ carriers in the 41 to 54 range was found in a small sample of 98 females from the United States diagnosed with iPD. 13 Similar results were reported in a Chinese sample of 147 females, 14 with the rate of 6.5% compared to 0.0% in a small sample of population controls. Most recently, an estimate of 11% of GZ allele carriers among females with iPD has been reported from the Movement Disorders Clinic in Denver, Colorado. 15 Here, we present the data from a much larger sample, which provides statistical evidence for the significant role of FMR1 GZ alleles as a risk factor for parkinsonism in females, and stimulates consideration of possible mechanisms of synergistic effect of these alleles with other iPDpredisposing factors.
Sample and Methods
We included 601 adult females clinically diagnosed with iPD by movement disorders experts, using the UK Brain Bank criteria. 5 This sample included 430 individuals from a larger cohort of iPD patients recruited since 2005 to participate in the QPP, as described previously, 4 and 171 subjects from the Australian Parkinson's Research Register encompassing three other states: Victoria, New South Wales, and Western Australia. The population-based control data were obtained from newborn Guthrie blood spots collected, in an anonymous fashion, from an unselected sample of 1,005 consecutive Australian females born in the State of Victoria in the years 2007-2008. A great majority of patients and controls were whites of European origin residing in Australia. Given that the screening of both groups was anonymous, we assumed, based on government data on ethnic composition of the general population, that both samples had a small admixture (<5%) of individuals of East and South-East Asian origin, which is the largest other ethnic group residing in this country.
Data collection and analysis from PD patients were approved by the Human Ethics Committees of Griffith University in Brisbane, and Monash and La Trobe Universities in Melbourne; screening of a control
sample of the Victorian newborns was approved by the Human Ethics Committee at the Royal Children's Hospital in Melbourne. All PD participants gave informed consent for their involvement in the study. CGG repeat size was measured on DNA extracted from whole blood or dry Guthrie blood spots. Testing of the major proportion of the iPD sample and of the Victorian newborn sample (for cross-checking and validation of dual samples) was performed at the MIND Institute, UC Davis, California, where genomic DNA was amplified using either a standard method 13 or a recently developed FMR1 PCR method 16, 17 utilizing primers flanking the CGG repeat sequence, in addition to internal repeat primers (Asuragen, Inc., Austin, TX). PCR products were subjected to capillary electrophoresis to determine allele size relative to known standards. Testing at the Victorian Clinical Genetics Services, Royal Children's Hospital in Melbourne, was conducted using PCR, 18 with all assays fully validated by internal and external quality assessment to provide a precision of 6 one repeat.
Results
We identified 49 GZ allele carriers (range, 41-54 CGGs) among 601 iPD females, compared with 52 in the sample of 1,005 Victorian female newborns, with the expansion in heterozygous state in all identified carriers. Using a two-sample test for proportions, this represents a significantly greater percentage of GZ carriers in the iPD cohort (8.2%) than in the populationbased cohort (5.2%), with the P value for the difference in proportions 5 0.009. Fisher's exact test generated a (two-sided) P value of 0.019 for this difference. The OR for the likelihood of being in the PD/GZ group was 1.62 with a 95% CI of 1.06 to 2.49.
Discussion
The present results provide evidence for a significant role of FMR1 GZ alleles as a risk factor for parkinsonism in females and are consistent with the findings from both Australian studies in iPD males, 3, 4 and also with the earlier findings in smaller female samples. [13] [14] [15] The population-based data are supported by clinical reports of the occurrence of a mild version of the fragile Xassociated tremor ataxia syndrome (FXTAS) in several male and female GZ carriers. [19] [20] [21] This syndrome was originally linked to FMR1 premutation alleles of 55 to 200 repeats, 9 and, although its core features are cerebellar ataxia and action tremor, approximately one third of those affected manifest parkinsonian features. 22, 23 The neurodegenerative changes in FXTAS have been attributed to a toxic gain-of-function effect of the elevated FMR1 mRNA resulting from CGG expansions in the premutation range. [8] [9] [10] [11] However, this mRNA elevation, though at a lower level, has also been reported in the carriers of GZ alleles with a threshold of 40 to 41 repeats, 7 which implies that the neurotoxic effect of this transcript may also apply to the GZ range, leading to neurodegenerative changes typical or reminiscent of FXTAS, 22, 23 or aggravating any existing pathologies underpinning parkinsonian manifestations. Indeed, neurological manifestations in a series of 31 adult carriers of GZ alleles in the 40 to 54 CGG range observed in movement disorders clinics in Denver and Chicago featured parkinsonism and/or ataxia and tremor. 15 However, the evidence based on the observed occurrence of these changes in individual GZ carriers is limited, because a causal relationship between the carrier status and neurological manifestations could not yet be confirmed by neuropathological data, or statistically verified. The most recent changes in the "required" molecular diagnostic criteria for FXTAS, which include GZ as well as PM carrier status, have been an important step forward. 24 However, the uncertainty of this association, if not yet fully supported by evidence, suggests that the term "not excluding" rather than "including" (in Fig. 1.4c ) might be considered.
A more effective approach enabling statistical analysis of the association between a particular set of clinical manifestations or other relevant findings and the GZ carrier status is to observe any differences in these changes between GZ carriers and noncarriers with a primary syndromic diagnosis of iPD. Our earlier results using this approach 25 suggested that, at the cellular (blood lymphoblasts) level, the toxic effect of the elevated FMR1 transcript in GZ carriers might contribute to cellular stress and the mitochondrial dysfunction long known to be associated with iPD, 26 and thus to the severity of parkinsonian manifestations. Indeed, in the same small sample, we found an elevation of the UPDRS (motor) score in GZ carriers compared to iPD controls matched for age and disease duration.
On the other hand, the effects of pathological processes linked to GZ alleles and to other iPDpredisposing factors, respectively, might synergize at brain level. A remarkable study using dopamine transporter ( 123 I) beta-CIT single-photon emission tomography imaging in 2 female and 1 male GZ carriers clinically diagnosed with iPD showed well-preserved dopamine transporter density in the putamen, implying an absence of dopaminergic deficits typically associated with this disorder. 27 These results suggest that the contribution of GZ alleles to the risk of parkinsonism may be related to mechanisms other than presynaptic dopaminergic insufficiency. The nature of these mechanisms has been suggested by MRI scanning, by which we have shown that total brain white matter changes in deep frontal and parieto-occipital regions are significantly more severe in GZ male carriers with PD than in age-matched noncarriers with PD. 28 These results imply that the additional damage inflicted by
the toxic gain-of-function RNA from the GZ alleles along the relevant nondopaminergic neural pathways may limit (presynaptic) compensatory responses at the earlier stages of the disorder. Considering that only a small proportion of iPD cases has so far been linked to a particular major gene, the potential importance of GZ alleles as a substantial risk factor in iPD is emphasized by their high population frequency, reaching 5% in females. 4, 6, 21, 22, 29, 30 Hence, the paucity of relevant large-scale studies is disconcerting, and may be partly accounted for by the requirement for relatively large sample sizes to obtain reliable estimates of the risk figures associated with GZ alleles from iPD cohorts. This was demonstrated by modelling the cumulative GZ allele frequency recorded in consecutive batches of 80 to 90 male newborn genotypes. 4 The results showed that this frequency fully stabilizes to the actual population estimate at a sample size of 2,000 alleles. Here, we have applied the same modeling to a sample of female newborn genotypes used as population controls, with the stabilization occurring at a sample size of 1,600 alleles.
In summary, our data, based on screening of a large cohort of female patients, consolidates the evidence for the role of GZ alleles in the risk of Parkinson's spectrum disorders and suggests pathological mechanisms involved in this allele's effect. An ongoing study being conducted by the authors in a large sample of GZ carriers with PD intends to establish whether these carriers represent a new, clinically, and/or radiologically separate subtype within the iPD spectrum, or whether it is a more severe form within the typical iPD phenotype. This will ultimately determine the criteria for standard testing for these alleles in clinical patients, and will allow for further exploration of specific targeted treatment.
